Evidence map›Paper›PMID 38110374›Full record

ArticleBMJ open2023

Acceptability of aspirin for cancer preventive therapy: a survey and qualitative study exploring the views of the UK general population.

Kelly E Lloyd, Louise H Hall, Lucy Ziegler, Robbie Foy, Sophie M C Green, Mairead MacKenzie, David G Taylor, Samuel G Smith, Aspirin for Cancer Prevention AsCaP Steering Committee

Open access · goldAbstract read
PubMed Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Kelly E LloydLeeds Institute of Health Sciences, University of Leeds Faculty of Medicine and Health, Leeds, UK k.e.lloyd@leeds.ac.uk.ORCID 0000-0002-0420-2342
Louise H HallLeeds Institute of Health Sciences, University of Leeds Faculty of Medicine and Health, Leeds, UK.
Lucy ZieglerLeeds Institute of Health Sciences, University of Leeds Faculty of Medicine and Health, Leeds, UK.
Robbie FoyLeeds Institute of Health Sciences, University of Leeds Faculty of Medicine and Health, Leeds, UK.ORCID 0000-0003-0605-7713
Sophie M C GreenLeeds Institute of Health Sciences, University of Leeds Faculty of Medicine and Health, Leeds, UK.
Mairead MacKenzieIndependent Cancer Patients' Voice, London, UK.
David G TaylorSchool of Pharmacy, University College London, London, UK.
Samuel G SmithLeeds Institute of Health Sciences, University of Leeds Faculty of Medicine and Health, Leeds, UK.ORCID 0000-0003-1983-4470
Aspirin for Cancer Prevention AsCaP Steering Committee
University of Leeds · GBThe Patients Association · GBUniversity College London · GB

Funding

Cancer Research UK 15015Cancer Research UK 19252Medical Research Council MC_UU_00004/02
6 · The paper itself

Abstract

objectivesAspirin could be offered for colorectal cancer prevention for the UK general population. To ensure the views of the general population are considered in future guidance, we explored public perceptions of aspirin for preventive therapy.

designWe conducted an online survey to investigate aspirin use, and awareness of aspirin for cancer prevention among the UK general population. We conducted semistructured interviews with a subsample of survey respondents to explore participants' acceptability towards aspirin for cancer preventive therapy. We analysed the interview data using reflexive thematic analysis and mapped the themes onto the Theoretical Domains Framework, and the Necessity and Concerns Framework.

settingOnline survey and remote interviews.

participantsWe recruited 400 UK respondents aged 50-70 years through a market research company to the survey. We purposefully sampled, recruited and interviewed 20 survey respondents.

resultsIn the survey, 19.0% (76/400) of respondents were aware that aspirin can be used to prevent cancer. Among those who had previously taken aspirin, 1.9% (4/216) had taken it for cancer prevention. The interviews generated three themes: (1) perceived necessity of aspirin; (2) concerns about side effects; and (3) preferred information sources. Participants with a personal or family history of cancer were more likely to perceive aspirin as necessary for cancer prevention. Concerns about taking aspirin at higher doses and its side effects, such as gastrointestinal bleeding, were common. Many described wanting guidance and advice on aspirin to be communicated from sources perceived as trustworthy, such as healthcare professionals.

conclusionsAmong the general population, those with a personal or family history of cancer may be more receptive towards taking aspirin for preventive therapy. Future policies and campaigns recommending aspirin may be of particular interest to these groups. Multiple considerations about the benefits and risks of aspirin highlight the need to support informed decisions on the medication.

Indexed as

AspirinNeoplasmsHumansQualitative ResearchSurveys and QuestionnairesUnited KingdomAspirinBehaviorDecision MakingGastrointestinal tumoursPREVENTIVE MEDICINE

Identifiers

PMID38110374
OpenAlexW4389915333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.